Abbott Laboratories received CE mark in Europe for the Tactiflex Duo ablation catheter to treat patients with atrial ...

Abbott Laboratories stock has reached a 52-week low, closing at $107.27. This marks a notable point for the healthcare company, as it navigates a challenging market environment. Over the past year, ...

Abbott's TactiFlex Duo Ablation Catheter, Sensor Enabled, is designed with dual-energy to treat atrial fibrillation patients with the most challenging cases It can ...

The outlook and technical action suggest Abbott Laboratories (NYSE: ABT) will lead healthcare names like Johnson & Johnson (NYSE: JNJ) higher in 2025. While each produced a solid quarter, Abbott ...

We’ve given the headline figures, but here’s a longer summary of Abbott’s Q2 earnings: Abbott Laboratories reported strong results for the second quarter of 2025, with total sales reaching $11.142 ...

Abbott Laboratories is undervalued by the market, despite its strong fundamentals and strategic moves in high-growth areas like diabetes care and weight-loss treatments. The company boasts a high net ...

Abbott stock skidded Wednesday after the S&P 500 health giant missed the Street's third-quarter sales forecast, but met earnings expectations and reiterated its full-year guidance. The sales miss is ...